Preclinical studies on prostate cancer cells demonstrated Ki (inhibition constant) of enzalutamide is 86 nM and the IC50 of enzalutamide to suppress widetype AR activation by testosterone based on reporter gene transcription assays is 219 nM. This evidence concerns the gene AR and prostate cancer.